Advanced Search:
Equity Index

MEDCL.PA - MEDINCELL

€9.59  0.14 (1.48%)

Updated: 12:00 May 5, 2024 EST

Next Session's AI Forecast

80.72%

Avg. Accuracy (AI)

€12.08

Next Week's AI Forecast

100%

Trend's Accuracy (AI)

€10.07

MEDINCELL's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

MEDINCELL - HISTORICAL DATA 6M

  • Last price

    €9.59

  • Daily change

    €0.14

  • Previous Close

    €9.45

  • Last Updated

    12:00 May 5, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
1.11 2.94 0.98 0.79 0.25

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
1.39 3.79 2.13 2.13 2.09

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
100% 100% 100% 100%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
% % %

RSI METRIC

RS Hour RSI Hour RS Day RSI Day

MEDINCELL Technical Analysis News

MEDINCELL

3 rue des FrEres LumiEre
Jacou 34830
France
33 4 67 02 13 67
https://www.medincell.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 138
Description

MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology. The company's products in development include mdc-IRM, a risperidone extended-release injectable suspension for use in the treatment of schizophrenia in adults; mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-ANG, an antipsychotic product for use in the treatment of schizophrenia; mdc-TTG for Covid-19 and its variants; mdc-GRT for organ transplant; mdc-WWM for contraception; mdc-STM for malaria; and mdc-IRM for neuroscience. MedinCell S.A. was incorporated in 2003 and is based in Jacou, France.

Corporate Governance

MedinCell S.A.’s ISS Governance QualityScore as of May 1, 2024 is 9. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 9; Compensation: 10.

MEDINCELL'S HOLDERS RANK

List of holders with stock participation in MEDINCELL.

Holder Rank Holder Shares Date Reported % Out Value